Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1562902A.

Trial Profile

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1562902A.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1; Influenza virus vaccine
  • Indications Influenza A virus infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Feb 2011 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Actual initiation date (1 May 2010) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top